{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:33:40Z","timestamp":1760142820359,"version":"build-2065373602"},"reference-count":57,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","award":["223250"],"award-info":[{"award-number":["223250"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant melanoma is a prevalent and aggressive cancer, with globally increasing incidences. While immune checkpoint inhibitors (ICIs) have prolonged the survival of patients with advanced melanoma over the last decade, this improvement comes with the risk of severe immune-related adverse events (irAEs). This systematic review investigates patient baseline characteristics (BCs) as predictive factors for developing severe gastrointestinal, hepatic, and pulmonary irAEs in patients treated with ipilimumab (anti-CTLA-4) and\/or nivolumab\/pembrolizumab (anti-PD-1). A systematic literature search was conducted in the Ovid databases MEDLINE and EMBASE on 22 April 2022, following the PRISMA guidelines. Out of 1694 articles, 13 were included in the final analysis. We analyzed BCs and the occurrence of severe colitis, hepatitis, and pneumonitis in 22 treatment arms and 3 treatment groups: anti-CTLA-4 (n = 2904), anti-PD-1 (n = 1301), or combination therapy (n = 822). However, missing data preclude a direct comparison of individual BCs and the association to specific irAEs between studies. Descriptive analysis did not identify any significant association between median age, gender distribution, or performance status and severe colitis, hepatitis, or pneumonitis for any of the three treatment groups. We call for greater transparency and standardization in the reporting of patient-specific irAEs.<\/jats:p>","DOI":"10.3390\/cancers16020250","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T07:38:31Z","timestamp":1704440311000},"page":"250","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors"],"prefix":"10.3390","volume":"16","author":[{"given":"Kremena Petrova","family":"Trichkova","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Bergen, 5009 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"G\u00f6rtler","sequence":"additional","affiliation":[{"name":"Department of Oncology and Medical Physics, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-2770","authenticated-orcid":false,"given":"Line","family":"Bj\u00f8rge","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Centre for Cancer Biomarkers CCBIO, University of Bergen, Jonas Lies vei 87, 5021 Bergen, Norway"},{"name":"Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Schuster","sequence":"additional","affiliation":[{"name":"Department of Oncology and Medical Physics, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway"},{"name":"Department of Clinical Science, Centre for Cancer Biomarkers CCBIO, University of Bergen, Jonas Lies vei 87, 5021 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_2","unstructured":"Cancer Registry of Norway (2022). Cancer in Norway 2021\u2014Cancer Incidence, Mortality, Survival and Prevalence in Norway, Cancer Registry of Norway."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3389\/fimmu.2019.00990","article-title":"Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma","volume":"10","author":"Yu","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.12.015","article-title":"Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E\/K-mutant advanced or metastatic melanoma","volume":"109","author":"Robert","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ijc.33768","article-title":"Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up","volume":"150","author":"Aamdal","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"633032","DOI":"10.3389\/fonc.2021.633032","article-title":"Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_17","unstructured":"HHS, U.S.D.o. (2017). United States Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CJI.0000000000000213","article-title":"The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis","volume":"41","author":"Tandon","year":"2018","journal-title":"J. Immunother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): Evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.14309\/ajg.0000000000000497","article-title":"Checkpoint Inhibitor-Induced Colitis","volume":"115","author":"Bellaguarda","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in Patients Treated With Anti-Programmed Death-1\/Programmed Death Ligand 1 Therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Brahmer","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials","volume":"40","author":"Unger","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102590","DOI":"10.1016\/j.autrev.2020.102590","article-title":"Immune checkpoint inhibitors-induced autoimmunity: The impact of gender","volume":"19","author":"Triggianese","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1634\/theoncologist.2016-0450","article-title":"Impact of age on outcomes with immunotherapy for patients with melanoma","volume":"22","author":"Betof","year":"2017","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/2326-6066.CIR-19-0986","article-title":"Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy","volume":"8","author":"Shah","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"786046","DOI":"10.3389\/fimmu.2021.786046","article-title":"Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy","volume":"12","author":"Wong","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"13773","DOI":"10.1038\/s41598-020-70743-2","article-title":"Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: A single-institution retrospective study","volume":"10","author":"Okada","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_33","first-page":"2867","article-title":"New Treatment Strategies for Patients with Advanced Melanoma","volume":"12","author":"King","year":"2022","journal-title":"Oncol. Pract. Manag."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomia","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-Analysis in Clinical Trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/CMR.0000000000000705","article-title":"Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced\/metastatic melanoma patients","volume":"31","author":"Zietek","year":"2021","journal-title":"Melanoma Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/imt-2020-0217","article-title":"First-line treatment of advanced\/metastatic melanoma with anti-PD-1 antibodies: Multicenter experience in Poland","volume":"13","author":"Zietek","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/CJI.0000000000000046","article-title":"Effectiveness and tolerability of ipilimumab: Experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions","volume":"37","author":"Eigentler","year":"2014","journal-title":"J. Immunother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/CAD.0000000000000629","article-title":"Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in the The Netherlands","volume":"29","author":"Jochems","year":"2018","journal-title":"Anti-Cancer Drugs"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1158\/1078-0432.CCR-21-0793","article-title":"Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules","volume":"27","author":"Long","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb\/IV CheckMate 511 Trial","volume":"37","author":"Lebbe","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study","volume":"21","author":"Maio","year":"2010","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_55","first-page":"9","article-title":"Ipilimumab efficacy and safety in patients with advanced melanoma: A retrospective analysis of HLA subtype from four trials","volume":"10","author":"Wolchok","year":"2010","journal-title":"Cancer Immun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_57","unstructured":"Alliance, M.R. (2022). MRA Annual Report 2021\u201322, Rural Development Academy."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/250\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:40:50Z","timestamp":1760103650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16020250"],"URL":"https:\/\/doi.org\/10.3390\/cancers16020250","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,1,5]]}}}